Skip to main content

28-10-2018 | Breast cancer | ESMO 2018 | Video

Tumor-infiltrating lymphocytes show prognostic potential in HER2-positive breast cancer

Maria Vittoria Dieci describes the ShortHER trial’s findings on tumor-infiltrating lymphocytes and their prognostic value in patients undergoing treatment for early HER2-positive breast cancer (6:03).

Please log in to get access to this content

SABCS 2021

Access news and expert commentary from the 2021 San Antonio Breast Cancer Symposium

Image Credits